### **Overview** Lasa Supergenerics Limited is a **vertically integrated manufacturer** specializing in **veterinary Active Pharmaceutical Ingredients (APIs)** with deep expertise in **catalyst chemistry**. Incorporated in 2011, the company has established itself as a **leading player in India’s veterinary API market** and is expanding its footprint globally. It is listed on both the **National Stock Exchange (NSE: LASA)** and the **Bombay Stock Exchange (BSE: 540702)**. Lasa serves over **500 global customers** across India, Australia, the Middle East, Latin America, China, Turkey, Egypt, Jordan, Korea, and other emerging markets. The company's product portfolio spans **veterinary, human, and animal feed ingredients**, with a strategic focus on **niché, high-margin APIs**. --- ### **Core Business & Vertical Integration** - **Value Chain Coverage**: Discovery → Manufacturing → Global Marketing. - **Fully backward-integrated** for key molecules, enabling control from **raw material sourcing to bulk API production**, minimizing dependency on external suppliers and insulating the supply chain from disruptions. - Operates **multi-purpose, GMP-certified manufacturing facilities** located in **Mahad and Chiplun, Maharashtra**, with historical combined capacity of **4,300 MT/year** (as per 2021 data). - As of September 2025, the company has **consolidated all manufacturing operations into a single advanced facility at MIDC Lote Parshuram**, Ratnagiri, to **enhance operational efficiency, reduce risks, and streamline compliance** following past disruptions (fire, floods, regulatory issues). --- ### **Product Portfolio & Key Strengths** - **Primary Products**: - **Veterinary APIs**: Albendazole (flagship), Fenbendazole, Oxfendazole, Ricobendazole, Oxyclozanide, Halquinol, Nitroxylene. - **Human APIs**: Progesterone (FDA-approved), Favipiravir (developed, not commercialized). - **Animal Feed Ingredients**: Halquinol (feed additive for poultry). - **Portfolio Size**: Over **37 products**, including 15 veterinary APIs, 2 human APIs, and 20 feed ingredients/therapeutic reagents. - **Revenue Distribution (FY20–H1 FY21)**: - Veterinary APIs: ~98% - Human APIs: ~2% (emerging segment) - **Key Revenue Drivers**: - **Albendazole**: ~65% of FY20 revenue; market size ~₹10,000 crore. - **Fenbendazole**: ~21%, Oxfendazole (~6%), Povidone Iodine (~2%). - **Progesterone (Human API)**: Targets ₹6,000 crore market; India imports 200 tons annually; Lasa has 50 MT capacity. --- ### **Strategic Differentiation** 1. **Catalyst Chemistry Leadership**: - Core competitive advantage in process innovation and catalytic efficiency. - Holds **multiple proprietary catalyst patents** (6+ key process patents), covering products contributing **over 85% of FY20 revenue**. - Patented processes reduce cycle time, raw material use, energy, and effluent, resulting in **cost efficiency, greener manufacturing, and higher margins**. - Recent patent: **Indian Patent No. 550071** (granted June 19, 2020) for preparation and purification of **5-Chloro-2-Nitroaniline**. 2. **Backward Integration**: - 95–98% of raw materials sourced **locally in India**, minimizing exposure to Chinese supply chains. - In-house production of key intermediates ensures supply reliability and cost control. 3. **R&D & Innovation**: - Strong focus on **process optimization, new product development, and regulatory compliance**. - Collaborations: With **Institute of Chemical Technology (ICT), Mumbai** – successfully synthesized **Favipiravir (2020)** and developed novel Progesterone synthesis. - Pipeline: Two **blockbuster Supergenerics (non-seasonal)** in late-stage development, each targeting ~₹2,000 crore market. 4. **Export Growth & Diversification**: - Exports now contribute **~50% of total sales** (direct + indirect); direct exports ~16–25%. - Expanding into **Russia, Latin America, Middle East, and Africa**. - Increasing exports driven by **China’s economic slowdown**, creating import substitution opportunities. --- ### **Capacity Expansion & Capital Projects** - **Albendazole Expansion (April 2025)**: - **20% capacity increase** via debottlenecking and new machinery. - Capital outlay: ~₹100 lakhs. - Improves supply reliability, lead time, and cost efficiency. - **Oxyclozanide Launch (2021)**: - 250 MT brownfield expansion at Chiplun plant. - Targets fascioliasis in livestock; limited global competition due to technical complexity. - Export certifications already secured. --- ### **Management & Leadership** - **Dr. Omkar P. Herlekar**, **Chairman & Managing Director**: - PhD in Science (ICT Mumbai); 40+ years in pharma/chemical sectors. - Former leadership roles at Kansai Nerolac, Valvoline Cummins, Deepak Novochem. - Spearheaded creation of **‘Catalyst Chemistry’ division** and drove backward integration, R&D, and global expansion. - Focus: **Research-driven growth, strategic planning, and regulatory compliance**.